The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Lysosomes as mediators of drug resistance in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
A Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543
The machinery of macroautophagy
Feng, Y., He, D., Yao, Z., & Klionsky, D. J. (2014) · Cell Research · doi:10.1038/cr.2013.168 · Cited by 2,083
A lysosome‐to‐nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
Settembre, C., Zoncu, R., Medina, D. L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M. C., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.32 · Cited by 1,920
De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Signals from the lysosome: a control centre for cellular clearance and energy metabolism
Settembre, C., Fraldi, A., Medina, D. L., & Ballabio, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3565 · Cited by 1,697
Cited by
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationModulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Self-citationHow the Warburg effect supports aggressiveness and drug resistance of cancer cells?
Icard, P., Shulman, S., Farhat, D., Steyaert, J.-M., Alifano, M., & Lincet, H. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.001 · Cited by 643
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Self-citationErin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Self-citationRole of lysosomes in physiological activities, diseases, and therapy
Zhang, Z., Yue, P., Lu, T., Wang, Y., Wei, Y., & Wei, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01087-1 · Cited by 356
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Self-citationSarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Self-citationThe role of alternative splicing in cancer: From oncogenesis to drug resistance
Sciarrillo, R., Wojtuszkiewicz, A., Assaraf, Y. G., Jansen, G., Kaspers, G. J. L., Giovannetti, E., & Cloos, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100728 · Cited by 307
Self-citationPhospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Kopecka, J., Trouillas, P., Gašparović, A. Č., Gazzano, E., Assaraf, Y. G., & Riganti, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100670 · Cited by 291
Self-citationZhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21739 · Cited by 270
Self-citationAutophagy and organelle homeostasis in cancer
Miller, D. R., & Thorburn, A. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.02.010 · Cited by 258
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Self-citationCathepsin B: A sellsword of cancer progression
Mijanović, O., Branković, A., Panin, A. N., Savchuk, S., Timashev, P., Ulasov, I., & Lesniak, M. S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.035 · Cited by 205
The mechanism of Warburg effect-induced chemoresistance in cancer
Liu, C., Jin, Y., & Fan, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698023 · Cited by 177
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Self-citationFGFR-TKI resistance in cancer: current status and perspectives
Yue, S., Li, Y., Chen, X., Wang, J., Li, M., Chen, Y., & Wu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01040-2 · Cited by 145
Lysosomes as Oxidative Targets for Cancer Therapy
Dielschneider, R. F., Henson, E. S., & Gibson, S. B. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3749157 · Cited by 123
“Many cancer cells have increased the number of lysosomes to maintain homeostasis by the increased degradation and recycling macromolecules to maintain cell proliferation and survive under stress condition in the microenvironment [4, 14, 15].”
BackgroundHanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Lysosomal trapping of palbociclib and its functional implications
Llanos, S., Megias, D., Blanco-Aparicio, C., Hernández-Encinas, E., Rovira, M., Pietrocola, F., & Serrano, M. (2019) · Oncogene · doi:10.1038/s41388-019-0695-8 · Cited by 96
Lucien, F., Pelletier, P.-P., Lavoie, R. R., Lacroix, J.-M., Roy, S., Parent, J.-L., Arsenault, D., Harper, K., & Dubois, C. M. (2017) · Nature Communications · doi:10.1038/ncomms15884 · Cited by 66
Yousef, M., Le, T. S., Zuo, J., Park, C., Chacra, N. B., Davies, N. M., & Löbenberg, R. (2023) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.363591 · Cited by 10
Metadata
- Authors
- Zhitomirsky, B., & Assaraf, Y. G.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 24
- Pages
- 23-33
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2187002261
- Cited by
- 482
- References
- 86
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.